Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

129.22 +0.03 (+0.03%)

Streaming Delayed Price Updated: 10:53 AM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,562,083
Open	130.09
Bid (Size)	129.20 (200)
Ask (Size)	129.26 (100)
Prev. Close	129.18
Today's Range	128.92 - 131.00
52wk Range	104.46 - 157.29
Shares Outstanding	1,253,809,440
Dividend Yield	2.54%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Today 3:00 EDT

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

June 04, 2026

From Gilead Sciences, Inc.

Via Business Wire

Performance

YTD	+6.3%	+6.3%
1 Month	-3.2%	-3.2%
3 Month	-11.0%	-11.0%
6 Month	+5.4%	+5.4%
1 Year	+18.5%	+18.5%

More News

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

Via The Motley Fool

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗

June 02, 2026

Via Benzinga

Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗

May 19, 2026

Via Chartmill

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

June 02, 2026

From Gilead Sciences, Inc.

Via Business Wire

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

June 01, 2026

Via Benzinga

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

Via The Motley Fool

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

May 27, 2026

From Gilead Sciences, Inc.

Via Business Wire

If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗

May 26, 2026

Via Benzinga

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗

May 24, 2026

Via MarketBeat

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

May 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

May 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

May 21, 2026

From Gilead Sciences, Inc.

Via Business Wire

Compugen Q1 Earnings Call Highlights ↗

May 18, 2026

Via MarketBeat

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗

May 17, 2026

Via MarketBeat

3 Market-Beating Stocks to Research Further

May 15, 2026

Via StockStory

Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026

From Gilead Sciences, Inc.

Via Business Wire

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗

May 14, 2026

Via MarketBeat

Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 14, 2026

Via StockStory

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead (GILD) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Via The Motley Fool

These S&P500 stocks are moving in today's pre-market session ↗

May 08, 2026

Via Chartmill

Frequently Asked Questions

Is Gilead Sciences publicly traded?

Yes, Gilead Sciences is publicly traded.

What exchange does Gilead Sciences trade on?

Gilead Sciences trades on the Nasdaq Stock Market

What is the ticker symbol for Gilead Sciences?

The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market

What is the current price of Gilead Sciences?

The current price of Gilead Sciences is 129.22

When was Gilead Sciences last traded?

The last trade of Gilead Sciences was at 06/05/26 10:53 AM ET

What is the market capitalization of Gilead Sciences?

The market capitalization of Gilead Sciences is 162.01B

How many shares of Gilead Sciences are outstanding?

Gilead Sciences has 162B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.